Loading…
Scinai Immunotherapeutics Ltd. is projected to decline to $0.2213 by 2027, a -14% move from its current price of $0.258. SCNI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.246 | $0.2577 | $0.2699 | -0.13% |
| Jul 14 | $0.241 | $0.2573 | $0.2748 | -0.25% |
| Jul 15 | $0.2371 | $0.257 | $0.2786 | -0.38% |
| Jul 16 | $0.2339 | $0.2567 | $0.2817 | -0.50% |
| Jul 17 | $0.2311 | $0.2564 | $0.2845 | -0.63% |
| Jul 18 | $0.2285 | $0.2561 | $0.2869 | -0.76% |
| Jul 19 | $0.2261 | $0.2557 | $0.2892 | -0.88% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2261 | $0.2557 | $0.2892 | -0.88% |
| Week 2 | $0.213 | $0.2535 | $0.3016 | -1.75% |
| Week 3 | $0.203 | $0.2512 | $0.3109 | -2.62% |
| Week 4 | $0.1947 | $0.249 | $0.3185 | -3.48% |
| Week 5 | $0.1875 | $0.2468 | $0.325 | -4.33% |
| Week 6 | $0.181 | $0.2447 | $0.3307 | -5.17% |
| Week 7 | $0.1752 | $0.2425 | $0.3358 | -6.00% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company based in Jerusalem, Israel, operating in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd.
and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
SCNI is a micro-cap biopharmaceutical stock trading at $0.255 with a market cap of $1.32M and a rank of 5498. The current price sits within a defined 30-day range, and the near-term technical setup shows neutral momentum. Long-run projections outline meaningful upside by 2030 and beyond, with substantial upside potential reflected in the 2050 forecast.
These figures provide a framework for the stock’s potential trajectory over time.
A major floor 67.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.7% away) — a key level to hold.
The nearest ceiling, 93.8% above — a clean break opens room to run.
A major ceiling 228.7% above — clearing it would confirm fresh momentum.
Key SCNI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SCNI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.2612 | Sell | $0.2595 | Sell |
| MA 10 | $0.2621 | Sell | $0.2679 | Sell |
| MA 20 | $0.2875 | Sell | $0.2981 | Sell |
| MA 50 | $0.4239 | Sell | $0.3984 | Sell |
| MA 100 | $0.5528 | Sell | $0.5482 | Sell |
| MA 200 | $0.8116 | Sell | $0.9209 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.52 | Neutral |
| Stoch RSI (14) | 68.23 | Neutral |
| CCI (20) | -80.11 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -12.24 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.02 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 40.11 | Neutral |
| Momentum (10) | -0.00 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 0.26 | Sell |
| ADX (14) | 32.47 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is Neutral. The RSI14 is 30, and the stock trades below the simple moving averages, with SMA50 at $0.4872 and SMA200 at $0.8763. There is defined support at $0.255 and resistance at $0.56, framing the near-term risk and reward.
The 30-day range runs from a low of $0.1794 to a high of $0.3624, highlighting recent volatility within a narrow price corridor.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.251 | $0.258 | $0.2803 | 0% | Neutral | |
| $0.1647 | $0.2213 | $0.3204 | -14% | Neutral | |
| $0.1614 | $0.2283 | $0.35 | -12% | Neutral | |
| $0.1615 | $0.2386 | $0.3822 | -8% | Neutral | |
| $0.20 | $0.3074 | $0.5106 | +19% | Neutral | |
| $0.1895 | $0.302 | $0.5176 | +17% | Neutral | |
| $0.1678 | $0.2768 | $0.488 | +7% | Neutral | |
| $0.1599 | $0.2725 | $0.4926 | +6% | Neutral | |
| $0.1389 | $0.2444 | $0.4521 | -5% | Neutral | |
| $0.1765 | $0.3203 | $0.6051 | +24% | Bullish | |
| $0.1709 | $0.3592 | $0.7404 | +39% | Bullish | |
| $0.2708 | $0.6018 | $1.38 | +133% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.251 | $0.258 | $0.3159 | +0.00% |
| August 2026 | $0.2018 | $0.2428 | $0.3033 | -5.88% |
| September 2026 | $0.1888 | $0.2299 | $0.2925 | -5.32% |
| October 2026 | $0.1897 | $0.2335 | $0.3015 | +1.54% |
| November 2026 | $0.1831 | $0.2274 | $0.2974 | -2.61% |
| December 2026 | $0.1691 | $0.2118 | $0.2803 | -6.86% |
Click any year to see its month-by-month SCNI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SCNI price prediction for 2026 points to an average of $0.258 (low $0.251, high $0.2803) — a potential gain of 0% on today's $0.258. Price action looks broadly range-bound.
In 2027, SCNI is projected to trade between $0.1647 and $0.3204, averaging $0.2213 — a potential decline of -14% from today's $0.258. That is -14% versus the projected 2026 average. A consolidation phase looks the most probable path here.
Scinai Immunotherapeutics Ltd.'s 2028 outlook centres on $0.2283, within a $0.1614 to $0.35 range. That is up +3% on the projected 2027 average. That marks a -12% change versus current levels. Price action looks broadly range-bound.
By 2029, SCNI could reach as high as $0.3822, with a base case around $0.2386 and support toward $0.1615 — roughly -8% from $0.258. A consolidation phase looks the most probable path here.
Expect SCNI to range from $0.20 to $0.5106 through 2030. The $0.3074 average target implies a +19% move from current prices. That is up +29% on the projected 2029 average. Price action looks broadly range-bound.
The SCNI price prediction for 2031 points to an average of $0.302 (low $0.1895, high $0.5176) — a potential gain of +17% on today's $0.258. A consolidation phase looks the most probable path here.
In 2032, SCNI is projected to trade between $0.1678 and $0.488, averaging $0.2768 — a potential gain of +7% from today's $0.258. That is -8% versus the projected 2031 average. Price action looks broadly range-bound.
Scinai Immunotherapeutics Ltd.'s 2033 outlook centres on $0.2725, within a $0.1599 to $0.4926 range. That is -2% versus the projected 2032 average. That marks a +6% change versus current levels. A consolidation phase looks the most probable path here.
By 2034, SCNI could reach as high as $0.4521, with a base case around $0.2444 and support toward $0.1389 — roughly -5% from $0.258. Price action looks broadly range-bound.
Expect SCNI to range from $0.1765 to $0.6051 through 2035. The $0.3203 average target implies a +24% move from current prices. That is up +31% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The SCNI price prediction for 2040 points to an average of $0.3592 (low $0.1709, high $0.7404) — a potential gain of +39% on today's $0.258. Momentum favours further upside here.
In 2050, SCNI is projected to trade between $0.2708 and $1.38, averaging $0.6018 — a potential gain of +133% from today's $0.258. That is up +68% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SCNI today (≈ 3,875.968992 SCNI) could be worth
$2,332.61
+$1,332.61 (+133%) by 2050 · US Dollar
Based on the average projected SCNI price of $0.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SCNIwould be worth at today's price.
$1,000 invested in SCNI on Jul 10, 2025 (≈ 434.782618 SCNI) would be worth
$112.17
-$887.83 (-88.8%) today · 0.11× · US Dollar
Based on a SCNI entry price of $2.3 vs. today's $0.258.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.27 | $955.56 | -4.4% |
| 1 month ago | $0.327 | $788.99 | -21.1% |
| 3 months ago | $0.581 | $444.06 | -55.6% |
| 6 months ago | $0.779 | $331.19 | -66.9% |
| 1 year ago | $2.3 | $112.17 | -88.8% |
| All time (5.0y) ago | $277 | $0.93 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SCNI forecast.
Our base-case forecast reaches $0.52 around 2050.
Implied market cap at $0.52: $2.69M
The multi-year forecast shows a bullish path in key milestones. For 2030, the min is $0.1941, the avg is $0.3145, the max is $0.5464, with a 23.3% ROI and a bullish sentiment. In 2040, the min is $0.1485, the avg is $0.33, the max is $0.7246, with a 29.4% ROI and a bullish sentiment.
By 2050, the min is $0.2625, the avg is $0.5832, the max is $1.34, with a 128.7% ROI and a bullish sentiment. The horizon includes years with negative returns (e.g., 2027 -13.7%, 2028 -15.5%, 2029 -10%), and other years with positive gains. These are estimates, not guarantees, and should be interpreted as forward-looking potential rather than fixed outcomes.
Tap a question to reveal the answer.
2030 min: $0.1941; avg: $0.3145; max: $0.5464; ROI: 23.3%; sentiment: BULLISH.
Forecasts show near-term mixed performance (2026 ROI 0%; 2027 ROI -13.7%; 2028 ROI -15.5%; 2029 ROI -10%) followed by upside (2030 ROI 23.3%; 2040 ROI 29.4%; 2050 ROI 128.7%). These are estimates, not guarantees, and should be weighed with prudent risk considerations.
The 2050 forecast lists a max of $1.34, indicating a path that could exceed $1 under the higher end of the projections, but these are not guaranteed and depend on future conditions.
Current price is $0.255 and market cap is $1.32M. The rank is 5498.
The 30-day picture shows NEUTRAL sentiment, RSI14 at 30, SMA50 of $0.4872, SMA200 of $0.8763. Support is at $0.255 and resistance at $0.56; the 30-day range is $0.1794 to $0.3624.
Scinai Immunotherapeutics Ltd. Community Discussion
0Share your Scinai Immunotherapeutics Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.